Results 191 to 200 of about 4,624,933 (258)

Glioblastoma cells utilize evolutionarily adapted cell metabolism to promote their malignant proliferation. [PDF]

Acta Neuropathol Commun
Bespalov MM, Gkini V, Iloglu Z, Yamada S, Nemoto A, Filppu P, Trontti K, Andriichuk L, Pietiläinen O, Le Joncour V, Nieminen AI, Laakkonen P, Namba T.   +12 more
europepmc   +1 more source

Single-cell analysis reveals KLF10-high macrophages induced by glioblastoma cells are associated with tumor progression. [PDF]

Front Immunol
Zhang X, Chen C, Fan Q, Chen S, Cao D, Hu Z, Zhou Y, Xu J, Wang D.   +8 more
europepmc   +1 more source

Morphofunctional Heterogeneity and Plasticity of Glioblastoma Cells Induced to Senescence by Temozolomide. [PDF]

Aging Cell
da Rosa SA, de Oliveira HQ, de Mendonça LB, de Oliveira NB, Jaeger MDC, Pereira LC, Oliveira FDP, Santos-Sousa D, Saez-Calazans F, Lenz L, Lakadamyali M, Lenz G, Filippi-Chiela EC.   +12 more
europepmc   +1 more source

Evaluating discrepancies between high‐yield neuroscience conditions in preclerkship medical education and national clinical incidence

Anatomical Sciences Education, EarlyView.
Abstract Medical education must balance foundational science with clinical relevance. Increasing emphasis on standardized assessments has led to prioritization of “high‐yield” conditions—those most likely to be assessed. Subsequently, educators and students often prioritize these conditions.
Kathryn Veazey, Oheneba Boadum
wiley   +1 more source

Exploring the Role of Long Non-Coding RNAs in Mediating Cisplatin Resistance in Glioma/Glioblastoma Cells. [PDF]

Int J Mol Sci
Sahrai H, Mosaddeghi-Heris R, Forghani N, Norouzi A, Zare S, Aghazadeh H, Bagheri K, Kocsis R, Ahmed F, Taheri N, Uddin S, Farzaneh M.   +11 more
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Metabolic targeting of pantothenate by medium chain fats in glioblastoma cells. [PDF]

BMC Cancer
Pain E, Singh PK, Khan Y, Mears G, Yang X, Lynham S, Devlin PF, Rutherford T, Jones KL, Walker MC, Beesley P, Gentry MS, Williams RS.   +12 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Endogenous Bornavirus-Like Nucleoprotein 1 Regulates Cellular Processes and DNA Double-Strand Breaks in U-87 MG Glioblastoma Cells. [PDF]

Cancer Rep (Hoboken)
Liang J, Zeng D, Guo Y, Jing C, Tang L, Luo Z, He P.   +6 more
europepmc   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source